

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1-118. (Canceled)
119. (Currently Amended) A ~~pharmaceutical~~ composition comprising an A $\beta$  peptide-A $\beta$ 1-7 linked to a carrier which is a toxoid from a pathogenic bacterium CRM197 to form a conjugate, wherein the A $\beta$  peptide is A $\beta$ 1-7.
120. (Currently Amended) The ~~pharmaceutical~~ composition of claim 119, wherein the conjugate comprises a plurality of additional copies of A $\beta$ 1-7.
121. (Currently Amended) The ~~pharmaceutical~~ composition of claim 119, which comprises at least 10  $\mu$ g of A $\beta$ 1-7.
122. (Currently Amended) The ~~pharmaceutical~~ composition of claim 119, which comprises at least 20  $\mu$ g of A $\beta$ 1-7.
123. (Currently Amended) The ~~pharmaceutical~~ composition of claim 119, which comprises at least 50  $\mu$ g of A $\beta$ 1-7.
124. (Currently Amended) The ~~pharmaceutical~~ composition of claim 119, which comprises at least 100  $\mu$ g of A $\beta$ 1-7.
125. (Currently Amended) The ~~pharmaceutical~~ composition of claim 119, wherein the carrier is CRM197 and A $\beta$ 1-7 is linked to CRM197 by chemical crosslinking.
126. (Currently Amended) The ~~pharmaceutical~~ composition of claim 125, wherein the amino terminus of A $\beta$ 1-7 is linked to CRM197.

127. (Currently Amended) The ~~pharmaceutical~~ composition of claim 125, wherein the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.

128. (Currently Amended) The ~~pharmaceutical~~ composition of claim 119, wherein the conjugate is expressed as a fusion protein.

129. (Currently Amended) The ~~pharmaceutical~~ composition of claim 128, wherein the toxoid is CRM197 and the amino terminus of A $\beta$ 1-7 is linked to CRM197.

130. (Currently Amended) The ~~pharmaceutical~~ composition of claim 128, wherein the toxoid is CRM197 and the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.

131. (Currently Amended) A ~~pharmaceutical~~ composition comprising (a) an A $\beta$  peptide A $\beta$ 1-7 linked to a carrier which is a toxoid from a pathogenic bacterium CRM197 to form a conjugate, wherein the A $\beta$  peptide is A $\beta$ 1-7 and (b) an adjuvant.

132. (Currently Amended) The ~~pharmaceutical~~ composition of claim 131, wherein the conjugate comprises a plurality of additional copies of A $\beta$ 1-7.

133. (Currently Amended) The ~~pharmaceutical~~ composition of claim 131, wherein the adjuvant comprises QS-21.

134. (Currently Amended) The ~~pharmaceutical~~ composition of claim 133, which comprises at least 10  $\mu$ g of A $\beta$ 1-7.

135. (Currently Amended) The ~~pharmaceutical~~ composition of claim 133, which comprises at least 20  $\mu$ g of A $\beta$ 1-7.

136. (Currently Amended) The ~~pharmaceutical~~ composition of claim 133, which comprises at least 50  $\mu$ g of A $\beta$ 1-7.

137. (Currently Amended) The ~~pharmaceutical~~ composition of claim 133, which comprises at least 100  $\mu\text{g}$  of A $\beta$ 1-7.

138. (Currently Amended) The ~~pharmaceutical~~ composition of claim 133, wherein the toxoid is CRM197 and A $\beta$ 1-7 is linked to the CRM197 by chemical crosslinking.

139. (Currently Amended) The ~~pharmaceutical~~ composition of claim 138, wherein the amino terminus of A $\beta$ 1-7 is linked to CRM197.

140. (Currently Amended) The ~~pharmaceutical~~ composition of claim 138, wherein the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.

141. (Currently Amended) The ~~pharmaceutical~~ composition of claim 133, wherein the conjugate is expressed as a fusion protein.

142. (Currently Amended) The ~~pharmaceutical~~ composition of claim 141, wherein the toxoid is CRM197 and the amino terminus of A $\beta$ 1-7 is linked to CRM197.

143. (Currently Amended) The ~~pharmaceutical~~ composition of claim 141, wherein the toxoid is CRM197 and the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.